Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Takeda
|
| gptkbp:acquisition |
gptkb:Cure_Vac_AG
|
| gptkbp:ceo |
Paul Bolno
|
| gptkbp:clinical_trial |
gptkb:Amyotrophic_lateral_sclerosis
gptkb:Duchenne_muscular_dystrophy Huntington's disease |
| gptkbp:collaborations |
gptkb:Harvard_University
gptkb:University_of_Oxford |
| gptkbp:focus |
genetic medicines
|
| gptkbp:founded |
gptkb:2012
|
| gptkbp:headquarters |
gptkb:Singapore
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wave Life Sciences
|
| gptkbp:partnership |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:products |
WVE-001
WVE-003 WVE-004 WVE-005 WVE-006 WVE-007 WVE-008 WVE-009 WVE-010 WVE-011 WVE-012 WVE-013 WVE-014 WVE-015 WVE-016 WVE-017 WVE-018 WVE-019 WVE-020 WVE-021 WVE-022 WVE-023 WVE-024 WVE-025 WVE-026 WVE-027 WVE-028 WVE-029 WVE-030 WVE-031 WVE-032 WVE-033 WVE-034 WVE-035 WVE-036 WVE-037 WVE-038 WVE-039 WVE-040 WVE-041 WVE-042 WVE-043 WVE-044 WVE-045 WVE-046 WVE-047 WVE-048 WVE-049 WVE-050 WVE-120101 |
| gptkbp:receives_funding_from |
$100 million
|
| gptkbp:research_focus |
RNA-targeted therapies
|
| gptkbp:symbol |
WVE
|
| gptkbp:technology |
nucleotide chemistry
|
| gptkbp:traded_on |
gptkb:NASDAQ
|